GlassScriptPhysician profile
Karissa Gable
NPI 1801028790
$203,121.06
in general payments reported to CMS, 2019-2025
11 companies · $65K in 2025
The $65K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35K · 2021: $1,500 · 2023: $52K · 2024: $50K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $95K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Honoraria: $8,000 · Travel and Lodging: $3,361 · Food and Beverage: $2,112 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,003.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,829.51 |
| Honoraria | $8,000.00 |
| Travel and Lodging | $3,361.46 |
| Food and Beverage | $2,112.33 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $52,776.80 | 2023-2025 | |
| Csl Behring | $47,409.38 | 2020-2025 | Hizentra, Privigen |
| Argenx US, INC. | $35,832.25 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $30,113.51 | 2023-2025 | Hyqvia |
| Grifols USA, LLC | $23,594.81 | 2024-2025 | Gamunex-C |
| Genzyme Corporation | $5,283.00 | 2023 | |
| Akcea Therapeutics, INC. | $4,028.42 | 2020 | |
| Gc Biopharma USA, INC. | $2,000.00 | 2025 | Alyglo |
| Astrazeneca Pharmaceuticals LP | $1,611.00 | 2023 | |
| Ucb, INC. | $471.89 | 2024-2025 | Zilbrysq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karissa Gable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.